TIMOPTIC-XE 0.5 %
TIMOLOL (TIMOLOL MALEATE) : 0.5 % · DIN 02171899 · ELVIUM LIFE SCIENCES
Health Canada status: MARKETED
What is TIMOPTIC-XE?
TIMOPTIC-XE 0.5 % contains TIMOLOL (TIMOLOL MALEATE) : 0.5 %. It is listed in the Health Canada Drug Product Database under DIN 02171899, held by ELVIUM LIFE SCIENCES, supplied as SOLUTION (EXTENDED RELEASE) for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 02-Sep-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TIMOPTIC-XE used for?
Reduction of elevated intraocular pressure.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is TIMOPTIC-XE called?
The same molecule, TIMOLOL, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Timoptol | Latin | Australia, Morocco |
| XALACOM | Latin | Czechia, Slovakia |
| Brinzolamid/timolol Olikla | Latin | Czechia, Slovakia |
| CUSIMOLOL | Latin | Morocco |
| FIXAPOST | Latin | Czechia |
| TIMOEYE | Latin | Australia |
| Timoptol XE | Latin | Australia |
| AKISTAN DUO | Latin | Czechia |
| AZARGA | Latin | Czechia |
| BIMATOPROST/TIMOLOL OLIKLA | Latin | Czechia |
| BRIMONIDIN/TIMOLOL OLIKLA | Latin | Czechia |
| COMBIGAN | Latin | Czechia, Slovakia |
| COSOPT | Latin | Czechia |
| COSOPT BEZ KONZERVA�N�CH P��SAD | Latin | Czechia |
| DORZOGEN COMBI | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02171899 |
|---|---|
| Brand name | TIMOPTIC-XE |
| Generic / active ingredient | TIMOLOL (TIMOLOL MALEATE) : 0.5 % |
| Manufacturer | ELVIUM LIFE SCIENCES |
| Strength | 0.5 % |
| Dosage form | SOLUTION (EXTENDED RELEASE) |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01ED01 TIMOLOL |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 02-Sep-2020 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02171899 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2171899 |
| Brand name | TIMOPTIC-XE |
| Active ingredient / INN | TIMOLOL (TIMOLOL MALEATE) : 0.5 % |
| ATC code | S01ED01 |
| ATC anatomical main group | S — Sensory organs |
| ATC therapeutic subgroup | S01 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | ELVIUM LIFE SCIENCES |
How is it administered?
One drop in the affected eye(s) once a day. Invert container and shake once before use. Other topical meds should be administered at least 10 minutes before TIMOPTIC-XE.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text sections (Section 11 header present but content truncated), though typically 15-30°C.
How is it supplied?
5 mL dispensers (translucent, high-density polyethylene) with a 2-piece cap assembly.
Which pack is which?
| Strength on the label | 0.5 % |
|---|---|
| Dosage form | SOLUTION (EXTENDED RELEASE) |
| Route | OPHTHALMIC |
| Packaging as described in the monograph | 5 mL dispensers (translucent, high-density polyethylene) with a 2-piece cap assembly. |
| Storage | Not explicitly detailed in provided text sections (Section 11 header present but content truncated), though typically 15-30°C. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity; reactive airway disease (asthma, severe COPD); sinus bradycardia; sick sinus syndrome; sino-atrial block; 2nd/3rd degree AV block; overt cardiac failure; cardiogenic shock.
Warnings and precautions
Systemic absorption may occur. Risk of cardiovascular/pulmonary reactions. May mask hypoglycemia in diabetics or thyrotoxicosis. Caution in patients with COPD or undergoing major surgery.
Is TIMOLOL in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code S01ED01 TIMOLOL. 7 of 35 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP-TIMOLOL | 0.5 % | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02447800 |
| SANDOZ TIMOLOL | 0.25 % | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02166712 |
| SANDOZ TIMOLOL | 0.5 % | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02166720 |
| TIMOLOL MALEATE-EX | 0.25 % | SOLUTION (EXTENDED RELEASE) | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02242275 |
| TIMOLOL MALEATE-EX | 0.5 % | SOLUTION (EXTENDED RELEASE) | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02242276 |
| TIMOPTIC | 0.5 % | SOLUTION | ELVIUM LIFE SCIENCES | MARKETED | DIN 00451207 |
| APO-TIMOP | 0.25 % | SOLUTION | APOTEX INC | DORMANT | DIN 00755826 |
| APO-TIMOP | 0.5 % | SOLUTION | APOTEX INC | DORMANT | DIN 00755834 |
| APO-TIMOP GEL | 0.25 % | SOLUTION (EXTENDED RELEASE) | APOTEX INC | APPROVED | DIN 02315858 |
| APO-TIMOP GEL | 0.5 % | SOLUTION (EXTENDED RELEASE) | APOTEX INC | DORMANT | DIN 02290812 |
Who else supplies TIMOLOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TIMOLOL appears in 178 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does TIMOLOL cost around the world?
TIMOLOL is listed on 14 national price registers Nexara tracks, across 243 pack listings published on 13 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 8 | 62 | 03 Sep 2026 |
| Czechia | max producer price (ex-factory) | 28 | 45 | 03 Sep 2026 |
| Slovakia | categorised final price | 14 | 23 | 02 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 22 | 22 | 03 Sep 2026 |
| Belgium | public | 18 | 18 | 01 Sep 2026 |
| Luxembourg | reimbursement | 17 | 17 | 05 Sep 2026 |
| Morocco | PPV (public price) | 8 | 17 | 05 Sep 2026 |
| Australia | ex-manufacturer | 3 | 9 | 08 Sep 2026 |
| South Africa | single exit price | 8 | 8 | 01 Sep 2026 |
| Greece | producer price (ex-factory) | 7 | 7 | 03 Sep 2026 |
| United Kingdom | hospital | 5 | 5 | 31 Aug 2026 |
| Spain | PVP con IVA (public price) | 4 | 4 | 05 Sep 2026 |
| Romania | max producer price | 4 | 4 | 03 Sep 2026 |
| Hungary | producer price (ex-factory) | 2 | 2 | 03 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.